# Shatavari Gains Commercial Momentum in Women's Health Segment

> Supplement manufacturers are increasing investment in shatavari formulations for PCOS, perimenopause, and lactation support. While preliminary clinical evidence shows promise in specific indications, the research base remains limited compared to established botanicals like ashwagandha, requiring consumers to manage expectations carefully.

**Published:** 2026-05-26T15:39:27.079504+00:00 · **Author:** dietarysupplement.ai · **Category:** Ingredients

[Web version](https://dietarysupplement.ai/news/shatavari-gains-commercial-momentum-in-women-s-health-segment-c8015123/) · [中文](https://dietarysupplement.ai/zh/news/shatavari-gains-commercial-momentum-in-women-s-health-segment-c8015123/)

![Shatavari Gains Commercial Momentum in Women's Health Segment](https://dietarysupplement.ai/images/news/shatavari-gains-commercial-momentum-in-women-s-health-segment-c8015123.png)

Shatavari Gains Commercial Momentum in Women's Health SegmentShatavari, a traditional Ayurvedic herb used for centuries in South Asian medicine, is entering mainstream Western supplement markets. Ingredient suppliers, contract manufacturers, and brands are developing formulations targeting polycystic ovary syndrome (PCOS), perimenopause symptoms, and lactation support. [According to Nutritional Outlook, shatavari is positioned as a next major botanical](https://www.nutritionaloutlook.com/view/shatavari-the-next-breakout-botanical) following the commercial trajectory of ashwagandha and other adaptogens. The botanical—scientifically named *Asparagus racemosus*—has moved from niche Ayurvedic circles into mainstream product development over the past 18–24 months, with industry analysts projecting significant category growth over the next three to five years driven by clinical interest and consumer demand for natural hormonal support.

## What happened
Multiple supplement manufacturers have launched or are developing shatavari-containing products targeting women's reproductive and hormonal health. [Industry sources indicate that shatavari's rise mirrors the trajectory of ashwagandha](https://www.nutritionaloutlook.com/view/shatavari-the-next-breakout-botanical), which evolved from specialized adaptogen to household supplement staple within approximately five years. Ingredient distributors report increased demand from brands seeking differentiated offerings in the women's wellness category, with formulations available as standalone products and in combination with other botanicals.

Market momentum reflects three primary drivers: emerging clinical research demonstrating efficacy in specific women's health indications; growing consumer familiarity with Ayurvedic botanicals; and supplement companies' strategic shift toward sex- and lifecycle-specific formulations. Brands have already commercialized shatavari products targeting lactation, hormonal balance, and stress resilience in women.

## What the research says
Shatavari contains steroidal saponins and alkaloids, compounds believed to modulate hormonal pathways relevant to estrogen signaling and immune function. The clinical evidence base is expanding but remains limited compared to ashwagandha. Current research suggests potential benefits in three areas:

- **PCOS and ovulatory dysfunction:** Small randomized controlled trials indicate shatavari may support ovulatory patterns and reduce elevated androgens in women with PCOS. One trial documented improvements in menstrual regularity and follicle maturation in approximately 40 women over 8–12 weeks at doses of 3–5 grams daily, though larger confirmatory studies are pending and sample sizes remain modest.
- **Lactation:** Observational and small clinical studies document increases in milk volume and fat content in women consuming shatavari during lactation, typically at doses of 3–8 grams daily. Evidence quality remains preliminary, and most studies originate from India or other Ayurvedic research centers, which may introduce publication bias.
- **Perimenopause and vasomotor symptoms:** Pilot trials report that 50–70% of perimenopausal women experienced reductions in hot flashes and night sweats, likely through phytoestrogen activity. However, sample sizes are small (n = 20–50), and larger controlled studies are needed.

No large phase 2 or 3 randomized controlled trials have been completed to date. Mechanistic research suggests shatavari functions as a mild adaptogen with anti-inflammatory and immunomodulatory properties, but human evidence for these broader claims is limited. The evidence base warrants caution against overconfident claims about efficacy.

## Beyond the headline
Shatavari's commercial emergence reflects the supplement industry's active segmentation of women's health. For decades, female-focused supplements were largely limited to prenatal vitamins and calcium formulations. Over the past five years, brands have invested in products targeting menstrual health, fertility, hormonal balance, and menopause—driven by consumer demand and clinical evidence for [adaptogens such as ashwagandha](/articles/best-adaptogens/).

The success of ashwagandha demonstrates that heritage botanicals can achieve premium market positioning when supported by clinical research and marketing investment. Shatavari follows this model: ingredient suppliers are investing in standardization of active saponin markers, contract manufacturers are scaling production, and brands are developing diverse delivery formats including capsules, powders, gummies, and liquid extracts.

Regulatory pathways favor commercialization. Shatavari is classified as a botanical dietary supplement under U.S. law, allowing manufacturers to make qualified structure-function claims (such as


## Sources
- [Shatavari: The Next Breakout Botanical](https://www.nutritionaloutlook.com/view/shatavari-the-next-breakout-botanical) — Nutritional Outlook

---

*This article was researched and drafted with [Claude AI](https://claude.com) (Anthropic) and Google Gemini, and reviewed by an editor before publication. See our [editorial policy](https://dietarysupplement.ai/about/editorial-policy/).*

*Disclaimer: This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, stopping, or combining supplements. These statements have not been evaluated by the FDA.*